Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects and Mechanisms of Extracellular Vesicles in Different Models of Acute Kidney Injury.

Stem cells international·2025

Same author

Meta-analysis of procalcitonin as a predictor for acute kidney injury.

Medicine·2021

Same author

Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China.

Pediatric cardiology·2018

Same author

Rho GTPases in A549 and Caco-2 cells dominating the endocytic pathways of nanocarbons with different morphologies.

International journal of nanomedicine·2018

Same author

Improving dispersive property, biocompatibility and targeting gene transfection of graphene oxide by covalent attachment of polyamidoamine dendrimer and glycyrrhetinic acid.

Colloids and surfaces. B, Biointerfaces·2018

Same author

Zwitterion Functionalized Silica Nanoparticle Coatings: The Effect of Particle Size on Protein, Bacteria, and Fungal Spore Adhesion.

Langmuir : the ACS journal of surfaces and colloids·2018

Search research articles

Related Experiment Video

Updated: May 15, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Targeted Therapy for ANCA Associated Vasculitis: Where Have We Been?

Liuyue Zeng¹, Huan Zhang¹, Dan Yang¹

¹North Sichuan Medical College, Nanchong, Sichuan, China.

Nephrology (Carlton, Vic.)

|May 14, 2026

Summary

Targeted biologics offer new hope for ANCA-associated vasculitis (AAV) treatment by addressing underlying immune pathways. Future strategies focus on personalized medicine for long-term, glucocorticoid-free remission.

Keywords:

ANCA‐associated vasculitis biologics pathophysiology renal vasculitis targeted therapy

More Related Videos

A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration

A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration

Published on: August 2, 2024

Related Experiment Videos

Last Updated: May 15, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration

A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration

Published on: August 2, 2024

Area of Science:

Rheumatology
Immunology
Internal Medicine

Background:

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) involves systemic small-vessel inflammation.
Current treatments (glucocorticoids, immunosuppressants) have toxicity and relapse issues.
Understanding AAV pathogenesis reveals new therapeutic targets.

Purpose of the Study:

To review advancements in targeted biologic therapies for AAV.
To analyze treatments based on distinct immunopathological pathways.
To discuss challenges and future directions in AAV management.

Main Methods:

Systematic review of targeted therapies for AAV.
Analysis of immunopathological pathways in AAV pathogenesis.
Evaluation of current biologic treatments and their limitations.

Main Results:

Targeted biologics represent a new treatment paradigm for AAV.
Progress has been made in therapies targeting neutrophils, B cells, T cells, complement, and cytokines.
Biologics face challenges: cost, variable efficacy, infection risk, biomarker scarcity.

Conclusions:

Biologics offer a promising avenue for AAV treatment.
Personalized precision medicine is crucial for future AAV management.
Goals include achieving long-term, glucocorticoid-free remission and optimizing treatment selection.